Boehringer Ingelheim and the University of Texas MD Anderson Cancer Center entered a multi-year partnership to conduct collaborative translational research for lung and GI cancers.
Boehringer Ingelheim has been forced to announce the planned
closure of a UK manufacturing site as a result of pricing pressures
that mean the firm is unable to produce unit dose vials (UDVs) at
the site cost-effectively.
Germany's Boehringer Ingelheim is claiming the number two spot
among the top 20 pharmaceutical companies for 2004 growth,
reporting double-digit gains for both revenues and operating
profit.
Boehringer Ingelheim and Slovenian company BIA Separations have
collaborated on a new separation and purification system that
should improve the production of plasmid DNA.
Germany's Boehringer Ingelheim has completed the validation process
for its new biopharmaceutical production plant in Biberach with a
positive inspection by the US Food and Drug Administration (FDA).